Ovarian cancer

Theratechnologies Receives FDA Agreement to Amended Trial Protocol for its Lead PDC Candidate Sudocetaxel Zendusortide

Retrieved on: 
Friday, June 2, 2023
Senior, American Society of Clinical Oncology, DLT, Toxicity, Part, EDT, ASCO, PDC, Patient, Lifting, TSX, FDA, Ovarian cancer, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, News, Society, Food, Safety, Body surface area, SORT1, Pharmaceutical industry

Today’s announcement also marks the lifting of the FDA’s partial clinical hold on the Phase 1 trial, following the Company’s voluntary pause of patient recruitment in December 2022.

Key Points: 
  • Today’s announcement also marks the lifting of the FDA’s partial clinical hold on the Phase 1 trial, following the Company’s voluntary pause of patient recruitment in December 2022.
  • In May 2023, Theratechnologies filed the amended trial protocol, which is designed to improve the therapeutic window of sudocetaxel zendusortide and extend its duration of therapy.
  • If deemed safe (0 or 1 DLT), the trial will enroll an additional six patients at the 2.5 mg/kg dose.
  • Those preliminary safety and efficacy data, which can be found here , informed the FDA-approved amended protocol.

Colorado State University Global Celebrates Graduates at Spring 2023 Commencement

Retrieved on: 
Friday, June 2, 2023
Aurora, Perseverance, Travel, Health administration, CSU, Friends, Colorado State University–Global Campus, Lieutenant, Parent, Assistant, Student, Dream, Humble High School, Faculty, The, Air force, Ovarian cancer, Health, Family, United States Department of the Air Force, Tutoring, Nursing

Aurora, Colo., June 02, 2023 (GLOBE NEWSWIRE) -- On Saturday, June 3, Colorado State University Global (CSU Global) will celebrate 1,026 undergraduate and graduate students earning their degrees at Spring 2023 Commencement.

Key Points: 
  • Aurora, Colo., June 02, 2023 (GLOBE NEWSWIRE) -- On Saturday, June 3, Colorado State University Global (CSU Global) will celebrate 1,026 undergraduate and graduate students earning their degrees at Spring 2023 Commencement.
  • They will join a network of over 30,000 CSU Global alumni across the globe.
  • “I have learned that we are a community; we flourish when we share our gifts, talents, and passions,” said Roth.
  • “The entire CSU Global community and I are thrilled to witness our graduates achieving their personal and professional goals and taking that next step in their career journeys.

New to The Street Announces its Corporate Guests TV Interviews, Airing as Episodes 474 and 475 with Shows Starting on Saturday, June 3, 2023, at 3:30 PM ET

Retrieved on: 
Friday, June 2, 2023
Survival rate, Endometriosis, AWH, Fox Business, Internet, OCLN, MasterCraft, Patient, Government, Mining, Disease, Massachusetts Institute of Technology, Letter, GPS, Interview, Atmosphere, Sewage, Water, OTCQB, FSE, Software, Forecasting, Pointman, Corporation, Diagnosis, SMX, CSE, PLC, Health, Cancer, Street, Women's health, Record, Nasdaq MarketSite, FRA, Gynaecology, LG, Ovarian cancer, Software as a service, Food, Woman, Gradient, OTC, OTCQX, Television, Cryptocurrency, Security (finance), Newsmax

Newsmax airs Episode 474 Saturday, June 3, 2023, at 3:30 PM ET, featuring the following Corporate Guests:

Key Points: 
  • Newsmax airs Episode 474 Saturday, June 3, 2023, at 3:30 PM ET, featuring the following Corporate Guests:
    2).
  • Precision Mapping Solutions – ProStar Holdings, Inc.'s (OTCQX: MAPPF) (TSXV: MAPS) (FSE: 5D00) ($MAPPF) interview with Page Tucker, Chief Executive Officer.
  • FOX Business Network airs Episode 475 Monday, June 5, 2023, at 10:30 PM PT, featuring the following Corporate Guests:
    2).
  • Gold/Silver Mining – Lahontan Gold Corp.'s (OTCQB: LGCXF) (TSXV: LG) ($LGCXF) interview with Kimberly Ann , Founder, CEO, President, and Director.

Florida Cancer Specialists & Research Institute Cutting-Edge Clinical Research Presented at 2023 ASCO® Annual Meeting

Retrieved on: 
Thursday, June 1, 2023
Abstract (summary), Education, Pulmonary embolism, Head, FACP, Cancer, Uveal melanoma, Research, Publication, Lung cancer, Doctor of Philosophy, ASCO, Clonal hematopoiesis, American Society of Clinical Oncology, MD, Patient, Physician, Melanoma, Annual general meeting, Drug development, Ovarian cancer, Breast cancer, Health, Society, Conference, FCS, Nursing, Pharmaceutical industry, Dietary supplement, Birth control, Medical imaging, Glass wool

FORT MYERS, Fla., June 1, 2023 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) physicians are presenting the outcomes of 23 clinical trials, the majority being Phase 1, at the 2023 American Society of Clinical Oncology (ASCO®) Annual Meeting on June 2 – 6 in Chicago, Illinois. With over 120 abstract sub-categories, attendees will learn about the most advanced treatments, research and innovations in oncology care on a global scale.

Key Points: 
  • Florida Cancer Specialists & Research Institute to present 23 abstracts/publications at 2023 ASCO Annual Conference.
  • Many of the featured studies being presented at the 2023 ASCO® Annual Meeting originated from trials conducted at the three FCS Phase 1 Drug Development Units and from late-phase studies conducted at FCS clinics located throughout Florida.
  • The American Society of Clinical Oncology (ASCO®) represents nearly 45,000 oncology professionals who care for people living with all forms of cancer.
  • Through research, education and promotion of high quality and equitable patient care, ASCO works to conquer cancer.

Zenith Epigenetics Reports Advancement of ZEN-3694 in NUT Carcinoma

Retrieved on: 
Thursday, June 1, 2023
CRPC, Neoplasm, Survival, NUT, CRADA, Quality of life, Lung cancer, Head, Prognosis, Carcinoma, NUT carcinoma, Neck, Bangladesh Technical Education Board, BET, Development, National Cancer Institute, Cancer, Cooperative research and development agreement, Patient, Colorectal cancer, Drug combination, Zenith, Diagnosis, CTEP, Ovarian cancer, Breast cancer, NCI, NIH, Disease, Pharmaceutical industry

Zenith's BET inhibitor ZEN-3694 providing significant clinical benefit in patients with aggressive cancer type

Key Points: 
  • Calgary, Alberta--(Newsfile Corp. - June 1, 2023) - Zenith Epigenetics Ltd. ("Zenith" or the "Company") reports clinical activity and the advancement in development of its BET inhibitor (BETi) ZEN-3694 in patients with NUT carcinoma (NC).
  • Zenith Epigenetics has provided ZEN-3694 to two NC patients for compassionate use and both experienced significant clinical benefit and durable reduction of their tumors.
  • "We are very pleased that NUT carcinoma patients receiving ZEN-3694 for compassionate use have benefitted from our drug," said Donald McCaffrey, CEO of Zenith Epigenetics.
  • We continue to advance these programs with our partners and are committed to bring this important therapy to these patients."

Zai Lab to Highlight New Data from its Oncology Pipeline at 2023 ASCO Annual Meeting

Retrieved on: 
Thursday, June 1, 2023
GIST, GSK, Stromal cell, Index, ADCC, Trae Elston, Research, Abdominal pain, PRIME, PFS, Trial of the century, CDC, ASCO, Vomiting, Development, Data analysis, American Society of Clinical Oncology, Poster, MD, Patient, Annual general meeting, Nausea, MTD, Infrared spectroscopy correlation table, Ovarian cancer, Society, Safety, Medical imaging, Pharmaceutical industry

SHANGHAI, China and CAMBRIDGE, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) will present three poster presentations with new data, including preliminary results from a clinical study evaluating its internal oncology research and development program ZL-1211, at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. ZL-1211 is an anti-Claudin (CLDN) 18.2 monoclonal antibody currently being evaluated for the treatment of unresectable or metastatic solid tumors.

Key Points: 
  • ZL-1211 is an anti-Claudin (CLDN) 18.2 monoclonal antibody currently being evaluated for the treatment of unresectable or metastatic solid tumors.
  • “We have been steadily expanding our oncology pipeline to include in-house research and development programs that are designed to reach patients globally, and we are pleased to share initial findings from our ZL-1211 program at this year’s ASCO meeting,” said Rafael Amado, MD, President, Head of Global Oncology Research and Development, Zai Lab.
  • Among the 10 evaluable patients included in the data analysis, the results showed ZL-1211 demonstrated a tolerable safety profile and preliminary antitumor effects.
  • Details regarding the Zai Lab presentations at the 2023 ASCO meeting are as follows:
    Preliminary results of a phase 1/2, first-in-human, open-label, dose escalation study of ZL-1211 (anti-Claudin 18.2 mAb) in patients with unresectable or metastatic solid tumors

Zentalis Announces Presentation of Positive Phase 1b Data Demonstrating Durable Responses and Favorable Safety Profile of Azenosertib in Combination with Chemotherapy at the 2023 ASCO Annual Meeting

Retrieved on: 
Thursday, May 25, 2023
Neutropenia, Obstetrics, Therapy, Neoplasm, Paclitaxel, Outer ring road, Gynecologic Oncology (journal), Medication, PLD, Carboplatin, Associate, IHC, Cyclin E1, Dana–Farber Cancer Institute, ASCO, WEE1, Patient, Division, SAN, Anemia, Cancer, HR, Washington University School of Medicine, Gynaecology, Immunohistochemistry, Poster, Ovarian cancer, Abstract, Thrombocytopenia, ORR, Pharmacology, Safety, Fatigue, Platinum, Pharmaceutical industry, Cyclin

Results will be presented in a poster discussion session at the 2023 ASCO Annual Meeting on June 5th (Abstract #5513).

Key Points: 
  • Results will be presented in a poster discussion session at the 2023 ASCO Annual Meeting on June 5th (Abstract #5513).
  • “The addition of azenosertib increased ORRs and mPFS over those observed historically with chemotherapy alone, or compared to adavosertib in combination with chemotherapy.
  • We are very encouraged by our robust chemotherapy combination data, particularly the strong efficacy and tolerability results when dosing azenosertib intermittently.
  • These data provide a compelling rationale to advance azenosertib into a registrational study in combination with either carboplatin or paclitaxel in Cyclin E1+ ovarian cancer.

Theratechnologies to Present Preliminary Safety and Efficacy Data from Phase 1 Trial of Sudocetaxel Zendusortide in Heavily Pretreated Cancer Patients at ASCO 2023

Retrieved on: 
Thursday, May 25, 2023
Part 1, Triple-negative breast cancer, TNBC, Index, Senior, SORT1, Part, American Society of Clinical Oncology, Diabetic neuropathy, Conjugation, BOR, MD Anderson Cancer Center, ASCO, Endometrial cancer, PDC, Patient, University, Part Two, TSX, MTD, Diagnosis, Toxic leukoencephalopathy, CDT, FDA, Therapy, Ovarian cancer, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, SD, Food, PR, Safety, Prostate cancer, Pharmaceutical industry, Dietary supplement

Based on the results presented at ASCO, Theratechnologies is engaged with the U.S. Food and Drug Administration (FDA) to amend the protocol of the Phase 1 clinical trial of sudocetaxel zendusortide.

Key Points: 
  • Based on the results presented at ASCO, Theratechnologies is engaged with the U.S. Food and Drug Administration (FDA) to amend the protocol of the Phase 1 clinical trial of sudocetaxel zendusortide.
  • The amendments are designed to improve the therapeutic window and allow for more prolonged therapy with sudocetaxel zendusortide, reflecting changes in patient selection and evaluation of alternative dosing regimens.
  • “The early efficacy data for our lead peptide-drug conjugate, sudocetaxel zendusortide, confirm that it rapidly internalizes and hyper-targets delivery of cytotoxic payload directly into cancer cells,” said Christian Marsolais, Ph.D., Senior Vice President and Chief Medical Officer at Theratechnologies.
  • The starting dose of 30 mg/m2 every 3 weeks (Q3W) was selected based on sudocetaxel zendusortide preclinical data.

Genelux Corporation Announces Publication of Positive Topline Data from Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) in Platinum-Resistant or Refractory Ovarian Cancer in the Journal of the American Medical Association (JAMA) On

Retrieved on: 
Thursday, May 25, 2023
Genelux Corporation, Bevacizumab, Duration, Response, Progression-free survival, JAMA, CI, NA, Article, Trae Elston, Woman, Gynecologic Oncology (journal), Oncology, Spotify, Abdominal pain, Associate, JAMA Oncology, PFS, Death, ITunes, City, Medical director, MD, Patient, Neoplasm, Ovarian cancer, ORR, Safety, Disease, Pharmaceutical industry, Medical device, Platinum, Fever

“We are incredibly pleased to have the Phase 2 trial data featured as an Original Investigation in such a prominent peer-reviewed journal.

Key Points: 
  • “We are incredibly pleased to have the Phase 2 trial data featured as an Original Investigation in such a prominent peer-reviewed journal.
  • ORR by RECIST1.1 was 54% (95% CI, 33%-74%), with Duration of Response of 7.6 months (95% CI, 3.7-9.6 months).
  • Median PFS by RECIST1.1 was 11.0 months (95% CI, 6.7-13.0 months), and 6-month PFS rate was 77% in all patients.
  • We believe the currently enrolling Phase 3 OnPrime/GOG-3076 clinical trial will hopefully provide more evidence that we can produce a life changing therapy."

Myriad Genetics Adds Folate Receptor Alpha to Precise™ Oncology Solutions Portfolio to Expand Treatment Options for Women Living with Ovarian Cancer

Retrieved on: 
Wednesday, May 24, 2023
Folate, Workflow, HRD, UC San Diego School of Medicine, MYGN, National Comprehensive Cancer Network, SALT, Genetics, Journal of the National Comprehensive Cancer Network, Patient, Reproductive Sciences, Department of Obstetrics and Gynecology (Massachusetts General Hospital), Medicine, Genetic testing, MIRV, Neoplasm, Oncology, FDA, Ovarian cancer, Myriad Genetics, Myriad, Medical imaging, Obstetrics, Gynaecology

SALT LAKE CITY, May 24, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the addition of Folate Receptor Alpha (FRα) to its Precise™ Oncology Solutions portfolio. The new biomarker adds another companion diagnostic option for providers to help guide treatment decisions for patients with ovarian cancer.

Key Points: 
  • SALT LAKE CITY, May 24, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the addition of Folate Receptor Alpha (FRα) to its Precise™ Oncology Solutions portfolio.
  • The new biomarker adds another companion diagnostic option for providers to help guide treatment decisions for patients with ovarian cancer.
  • FRα is a biomarker commonly expressed in patients with ovarian cancer.
  • FRα is a newly recommended biomarker test included in the National Comprehensive Cancer Network treatment guidelines for ovarian cancer.